203 related articles for article (PubMed ID: 22056259)
1. [Vitiligo and morphea: autoimmune cutaneous side effects of interferon treatment].
Martínez-García S; Fernández-Ballesteros MD; Segura-Palacios JM
Actas Dermosifiliogr; 2012 Apr; 103(3):250-1. PubMed ID: 22056259
[No Abstract] [Full Text] [Related]
2. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
3. Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo.
Nishitani N; Bito T; Ikeda T; Tokura Y; Nishigori C
J Dermatol; 2010 Aug; 37(8):770-2. PubMed ID: 20649729
[No Abstract] [Full Text] [Related]
4. Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha.
White JM; Devereux S; Pagliuca A; Salisbury JR; du Vivier AW; Creamer D
Br J Dermatol; 2006 Sep; 155(3):621-3. PubMed ID: 16911292
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune response as a side effect of treatment with interferon-α in melanoma: does this have prognostic implications?
Palacios-Álvarez I; Román-Curto C; Mir-Bonafé JM; Cañueto J; Usero-Bárcena T; Fernández-López E
Int J Dermatol; 2015 Mar; 54(3):e91-3. PubMed ID: 25521221
[No Abstract] [Full Text] [Related]
6. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
Fox M; Tahan S; Kim CC
Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
[TBL] [Abstract][Full Text] [Related]
7. [Complete remission of Crohn's disease after high-dose alpha-interferon treatment for malignant melanoma].
Ferre Aracil C; Rodríguez de Santiago E; García García de Paredes A; Aguilera Castro L; Soria Rivas A; López SanRomán A
Gastroenterol Hepatol; 2016; 39(6):397-400. PubMed ID: 26096290
[No Abstract] [Full Text] [Related]
8. A lupus-like reaction to subcutaneous interferon-α at injection sites.
Chodkiewicz HM; Cohen PR; Kim KB; Ivan D; Gershenwald JE
J Drugs Dermatol; 2012 Mar; 11(3):393-8. PubMed ID: 22395592
[TBL] [Abstract][Full Text] [Related]
9. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
Agarwala SS
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
11. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
[No Abstract] [Full Text] [Related]
12. Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186).
Sulkes A; Schachter J
Ann Oncol; 2002 Apr; 13(4):637. PubMed ID: 12056717
[No Abstract] [Full Text] [Related]
13. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury A; El Sayed F; Farah C; Bazex J
J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
[No Abstract] [Full Text] [Related]
14. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
[TBL] [Abstract][Full Text] [Related]
15. Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.
Siegelmann-Danieli N; Bardo M; Law A; Fisk D; Bernath A
Isr Med Assoc J; 2004 Oct; 6(10):636-7. PubMed ID: 15473596
[No Abstract] [Full Text] [Related]
16. How to manage melanoma in a psoriatic patient.
Papadavid E; Psyrri A; Pectasides D; Katoulis A; Balamoti E; Dalamaga M; Stavrianeas N
Dermatology; 2008; 216(3):277-8. PubMed ID: 18196939
[No Abstract] [Full Text] [Related]
17. More on cutaneous reactions to recombinant cytokine therapy.
Le Gal FA; Paul C; Chemaly P; Dubertret L
J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
[No Abstract] [Full Text] [Related]
18. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
Johnson DM; Hayat SQ; Burton GV
J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
[No Abstract] [Full Text] [Related]
19. Association of vitiligo, morphea, and Hashimoto's thyroiditis.
Dervis E; Acbay O; Barut G; Karaoglu A; Ersoy L
Int J Dermatol; 2004 Mar; 43(3):236-7. PubMed ID: 15009403
[No Abstract] [Full Text] [Related]
20. Management of cutaneous melanoma.
Tsao H; Atkins MB; Sober AJ
N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
